BR112021022031A2 - Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica - Google Patents
Composto, composição farmacêutica, e, formulação farmacêutica para administração tópicaInfo
- Publication number
- BR112021022031A2 BR112021022031A2 BR112021022031A BR112021022031A BR112021022031A2 BR 112021022031 A2 BR112021022031 A2 BR 112021022031A2 BR 112021022031 A BR112021022031 A BR 112021022031A BR 112021022031 A BR112021022031 A BR 112021022031A BR 112021022031 A2 BR112021022031 A2 BR 112021022031A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical
- topical administration
- pharmaceutical formulation
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19174586 | 2019-05-15 | ||
| PCT/EP2020/063518 WO2020229622A1 (en) | 2019-05-15 | 2020-05-14 | Treatment of cutaneous lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022031A2 true BR112021022031A2 (pt) | 2021-12-28 |
Family
ID=66554234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022031A BR112021022031A2 (pt) | 2019-05-15 | 2020-05-14 | Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20220241284A1 (https=) |
| EP (1) | EP3968997B1 (https=) |
| JP (2) | JP7734587B2 (https=) |
| KR (1) | KR20220008893A (https=) |
| CN (1) | CN113825512A (https=) |
| AU (1) | AU2020275208B2 (https=) |
| BR (1) | BR112021022031A2 (https=) |
| CA (1) | CA3137247A1 (https=) |
| IL (1) | IL288011A (https=) |
| MX (1) | MX2021012874A (https=) |
| SG (1) | SG11202110777XA (https=) |
| TW (1) | TWI863995B (https=) |
| UA (1) | UA129431C2 (https=) |
| WO (1) | WO2020229622A1 (https=) |
| ZA (1) | ZA202107300B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202989A1 (en) | 2022-04-20 | 2023-10-26 | Leo Pharma A/S | Treatment of frontal fibrosing alopecia |
| WO2024194105A1 (en) * | 2023-03-17 | 2024-09-26 | Leo Pharma A/S | A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema |
| WO2025085050A1 (en) * | 2023-10-16 | 2025-04-24 | Leo Pharma A/S | Treatment of frontal fibrosing alopecia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697342A2 (en) * | 2003-09-08 | 2006-09-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US20070264317A1 (en) * | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| US8883838B2 (en) * | 2010-12-03 | 2014-11-11 | Allergan, Inc. | Pharmaceutical cream compositions and methods of use |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2016112208A2 (en) * | 2015-01-09 | 2016-07-14 | Kineta One, Llp | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation |
| PT3297605T (pt) * | 2015-05-21 | 2022-05-30 | Dermavant Sciences GmbH | Composições farmacêuticas tópicas |
| DK3405197T3 (da) * | 2016-01-21 | 2023-11-27 | Leo Pharma As | Topisk behandling af håndeksem |
-
2020
- 2020-05-14 KR KR1020217041029A patent/KR20220008893A/ko not_active Ceased
- 2020-05-14 EP EP20724533.3A patent/EP3968997B1/en active Active
- 2020-05-14 AU AU2020275208A patent/AU2020275208B2/en active Active
- 2020-05-14 JP JP2021562843A patent/JP7734587B2/ja active Active
- 2020-05-14 WO PCT/EP2020/063518 patent/WO2020229622A1/en not_active Ceased
- 2020-05-14 CA CA3137247A patent/CA3137247A1/en active Pending
- 2020-05-14 BR BR112021022031A patent/BR112021022031A2/pt unknown
- 2020-05-14 UA UAA202107241A patent/UA129431C2/uk unknown
- 2020-05-14 MX MX2021012874A patent/MX2021012874A/es unknown
- 2020-05-14 US US17/610,787 patent/US20220241284A1/en active Pending
- 2020-05-14 SG SG11202110777XA patent/SG11202110777XA/en unknown
- 2020-05-14 CN CN202080035580.1A patent/CN113825512A/zh active Pending
- 2020-05-15 TW TW109116313A patent/TWI863995B/zh active
-
2021
- 2021-09-28 ZA ZA2021/07300A patent/ZA202107300B/en unknown
- 2021-11-11 IL IL288011A patent/IL288011A/en unknown
-
2025
- 2025-05-13 JP JP2025080666A patent/JP2025114800A/ja active Pending
- 2025-11-11 US US19/385,693 patent/US20260069595A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020275208A1 (en) | 2021-10-28 |
| UA129431C2 (uk) | 2025-04-23 |
| JP2025114800A (ja) | 2025-08-05 |
| KR20220008893A (ko) | 2022-01-21 |
| CN113825512A (zh) | 2021-12-21 |
| EP3968997B1 (en) | 2026-03-18 |
| EP3968997A1 (en) | 2022-03-23 |
| AU2020275208B2 (en) | 2025-12-04 |
| US20260069595A1 (en) | 2026-03-12 |
| TWI863995B (zh) | 2024-12-01 |
| WO2020229622A1 (en) | 2020-11-19 |
| CA3137247A1 (en) | 2020-11-19 |
| TW202106690A (zh) | 2021-02-16 |
| JP7734587B2 (ja) | 2025-09-05 |
| JP2022533526A (ja) | 2022-07-25 |
| SG11202110777XA (en) | 2021-11-29 |
| MX2021012874A (es) | 2021-11-17 |
| US20220241284A1 (en) | 2022-08-04 |
| IL288011A (en) | 2022-01-01 |
| ZA202107300B (en) | 2025-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022031A2 (pt) | Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica | |
| CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| SV2009003288A (es) | Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis | |
| UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
| IL316851A (en) | Preparations that are pharmaceutical emulsions for topical use containing 5,3-dihydroxy-4-isopropyl-trans-stilbene and their use for the treatment or prevention of dermatological conditions or disorders | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EA201500553A1 (ru) | Многодневный пластырь для чрескожного введения ротиготина | |
| BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| FI4218725T3 (fi) | Pehmeiden antikolinergisten analogien formulaatio | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| MX2023010491A (es) | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. | |
| DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
| BRPI0519280A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto | |
| BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
| CY1126388T1 (el) | Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων | |
| CR20190298A (es) | Amidas aromáticas de ácido carboxílico | |
| BR112022018654A2 (pt) | Formulações de oligossacarídeo de agonistas do receptor opioide kappa | |
| BR112015027247A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas | |
| BR112018005771A2 (pt) | composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata. | |
| BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
| NZ764238A (en) | Liquid formulation comprising paeonol and apocynin | |
| BR112023001585A2 (pt) | Composto, e, composição farmacêutica para a prevenção ou tratamento de dor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |